Cisplatin, vinblastine, and bleomycin in the treatment of metastatic melanoma

A phase II study of the southeastern cancer study group

D. H. Johnson, C. Presant, L. Einhorn, A. A. Bartolucci, F. A. Greco

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Fifty-one patients with metastatic melanoma were treated with cisplatin, vinblastine, and bleomycin. Of the 50 evaluable patients, 11 (22%) achieved an objective response, including three complete (6%) and eight partial (16%) responses. Four of the 11 responding patients had previously received dacarbazine; the remaining patients had received no prior chemotherapy. Responses were noted in cutaneous and lymph node sites as well as visceral metastases. However, with one exception, all responding patients with visceral involvement had lung metastases. Response duration were brief and toxicity was substantial. Nadir leukocyte counts <0.5 x 109/L occurred in 28% of the patients. Debilitating neurotoxicity, primarily paralytic ileus, and severe nausea and emesis were experienced by 24% of the patients. The combination of cisplatin, vinblastine, and bleomycin is not sufficiently beneficial to warrant its use in metastatic melanoma.

Original languageEnglish (US)
Pages (from-to)821-824
Number of pages4
JournalCancer Treatment Reports
Volume69
Issue number7-8
StatePublished - 1985

Fingerprint

Vinblastine
Cisplatin
Melanoma
Neoplasms
Bleomycin
Therapeutics
Neoplasm Metastasis
Intestinal Pseudo-Obstruction
Dacarbazine
indium-bleomycin
Leukocyte Count
Nausea
Vomiting
Lymph Nodes
Drug Therapy
Lung
Skin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cisplatin, vinblastine, and bleomycin in the treatment of metastatic melanoma : A phase II study of the southeastern cancer study group. / Johnson, D. H.; Presant, C.; Einhorn, L.; Bartolucci, A. A.; Greco, F. A.

In: Cancer Treatment Reports, Vol. 69, No. 7-8, 1985, p. 821-824.

Research output: Contribution to journalArticle

@article{12f5464f6f0e4fb38d18c4f6a8be1259,
title = "Cisplatin, vinblastine, and bleomycin in the treatment of metastatic melanoma: A phase II study of the southeastern cancer study group",
abstract = "Fifty-one patients with metastatic melanoma were treated with cisplatin, vinblastine, and bleomycin. Of the 50 evaluable patients, 11 (22{\%}) achieved an objective response, including three complete (6{\%}) and eight partial (16{\%}) responses. Four of the 11 responding patients had previously received dacarbazine; the remaining patients had received no prior chemotherapy. Responses were noted in cutaneous and lymph node sites as well as visceral metastases. However, with one exception, all responding patients with visceral involvement had lung metastases. Response duration were brief and toxicity was substantial. Nadir leukocyte counts <0.5 x 109/L occurred in 28{\%} of the patients. Debilitating neurotoxicity, primarily paralytic ileus, and severe nausea and emesis were experienced by 24{\%} of the patients. The combination of cisplatin, vinblastine, and bleomycin is not sufficiently beneficial to warrant its use in metastatic melanoma.",
author = "Johnson, {D. H.} and C. Presant and L. Einhorn and Bartolucci, {A. A.} and Greco, {F. A.}",
year = "1985",
language = "English (US)",
volume = "69",
pages = "821--824",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "7-8",

}

TY - JOUR

T1 - Cisplatin, vinblastine, and bleomycin in the treatment of metastatic melanoma

T2 - A phase II study of the southeastern cancer study group

AU - Johnson, D. H.

AU - Presant, C.

AU - Einhorn, L.

AU - Bartolucci, A. A.

AU - Greco, F. A.

PY - 1985

Y1 - 1985

N2 - Fifty-one patients with metastatic melanoma were treated with cisplatin, vinblastine, and bleomycin. Of the 50 evaluable patients, 11 (22%) achieved an objective response, including three complete (6%) and eight partial (16%) responses. Four of the 11 responding patients had previously received dacarbazine; the remaining patients had received no prior chemotherapy. Responses were noted in cutaneous and lymph node sites as well as visceral metastases. However, with one exception, all responding patients with visceral involvement had lung metastases. Response duration were brief and toxicity was substantial. Nadir leukocyte counts <0.5 x 109/L occurred in 28% of the patients. Debilitating neurotoxicity, primarily paralytic ileus, and severe nausea and emesis were experienced by 24% of the patients. The combination of cisplatin, vinblastine, and bleomycin is not sufficiently beneficial to warrant its use in metastatic melanoma.

AB - Fifty-one patients with metastatic melanoma were treated with cisplatin, vinblastine, and bleomycin. Of the 50 evaluable patients, 11 (22%) achieved an objective response, including three complete (6%) and eight partial (16%) responses. Four of the 11 responding patients had previously received dacarbazine; the remaining patients had received no prior chemotherapy. Responses were noted in cutaneous and lymph node sites as well as visceral metastases. However, with one exception, all responding patients with visceral involvement had lung metastases. Response duration were brief and toxicity was substantial. Nadir leukocyte counts <0.5 x 109/L occurred in 28% of the patients. Debilitating neurotoxicity, primarily paralytic ileus, and severe nausea and emesis were experienced by 24% of the patients. The combination of cisplatin, vinblastine, and bleomycin is not sufficiently beneficial to warrant its use in metastatic melanoma.

UR - http://www.scopus.com/inward/record.url?scp=0021932956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021932956&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 821

EP - 824

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 7-8

ER -